

Anti- Factor XIIIa [F13A1/1683]

Catalog No.	Description		
AMC40-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
AMC40-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive TM Detection Systems and i6000 TM Automated Staining Systems		
MUC40-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
MUC40-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
AXC40-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx [®] Elite Staining System, 160 tests		
AXC40-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx [®] Elite Staining System, 50 tests		

Clone	Species	Ig Class
F13A1/1683	Mouse	IgG2b

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of Factor XIIIa in formalin-fixed, paraffinembedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

Factor XIIIa is an 83kDa blood proenzyme and subunit of last zymogen, Factor XIII. It catalyzes the formation of gammaglutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It is involved in clotting cascade and also crosslinks alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIIIa has been identified in platelets, megakaryocytes, monocytes, macrophages and fibroblast-like mesenchymal or histiocytic cells in the uterus, placenta, prostate, and dermal dendritic cells. The expression of factor XIIIa is useful in differentiating between dermatofibroma (90% (+)), dermatofibrosarcoma protuberans (25%(+)) and desmoplastic malignant melanoma (0%(+)). It is a dermal dendrocyte marker and its expression is also seen in capillary hemagioblastoma, hemangioendothelioma, hemangiopericytoma, xanthogranuloma, hepatocellular carcinoma, glomus tumor, and meningiomas.

Emergo Europe, Prinsessegracht 20, 2514AP The Hague, The Netherlands

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The <u>primary antibody</u> may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody Factor XIIIa is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations	
Control Tissue	Stomach tissue as available with Biogenex FB-C40M* & FG-C40M*	
Recommended Dilution for Concentrated Antibody	1:10-50 in HK941	
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)	
Recommended	EZ-AR2 Elegance	
Pretreatment (Xmatrx)	(HX032-YCD)	
Antibody Incubation (Manual/i6000)	30-60 Min at RT	
Antibody Incubation (Xmatrx)	30-60 Min at 25°C	
Detection System for Manual, Xmatrx & i6000 systems***	Use BioGenex Two-Step OR One-Step Super Sensitive [™] Polymer-HRP IHC Detection System/DAB; see p. 2 for more	

Category	Antibodies	Revision No.	В
Document No.	932-C40M-EN	Release Date	22-Feb-2022



information
imomation

*FB: positive control micro chamber slides, FG: positive control microscopic slides. Xmatrx requires micro chamber slides.

**Pretreatment times will vary based on individual microwave power.

***For automation systems (Xmatrx-Elite & i6000 Diagnostics). refer to the factory protocols provided with the instrument

Detection	Two-Step	One-Step	Link and
System	HRP Kit	HRP Kit	Label Kit
Manual	QD440-XAKEN (1000 Test) QD430-XAKEN (1000 Test)	QD630-XAKEN (1000 Test)	QP300-XAKE (1000 Test)
Manual	QD420-YIKEN (500 Test) QD400-60KEN (60 Test)	QD620-XAKEN (500 Test)	QP900-9LE (500 Test)
Xmatrx -	QD550-YCDE	QD610-YADE	N/A
Automation	(200 Test)	(200 Test)	
i6000 -	QD410-YAXE	QD610-YAXE	N/A
Automation	(200 Test)	(200 Test)	
For more information, visit www.biogenex.com.			

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

Expected Results

This antibody stains cytoplasm in positive cells in formalinfixed, paraffin embedded tissue sections. An example image of a

tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medicallyestablished diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

1. Davie, EW. et al. 1991. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30: 10363-10370.

2°C 8°C	Temperature Limitation	IVD	In Vitro Diagnostic Medical Device
\boxtimes	Use By Date	LOT	Batch Code
NON STERILE	Non-Sterile	[]i	Consult Instructions for Use
EC REP	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	В
Document No.	932-C40M-EN	Release Date	22-Feb-2022